HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck.

Abstract
Recently, we characterized fibroblast growth factor receptor 1 amplification as a target for a rational therapy in lung squamous cell carcinoma. Patients harboring this genetic event are currently eligible for treatment with antifibroblast growth factor receptor small-molecule inhibitors in phase I clinical trials. This has the potential to significantly improve standard therapy for lung squamous cell carcinoma patients. The aim of this study was to elucidate whether fibroblast growth factor receptor 1 amplification is also a common genetic event in head and neck squamous cell carcinoma. For this purpose, we assembled a cohort of 555 patients, including 264 with metastatic disease and 147 with recurrent disease. Formalin-fixed, paraffin-embedded material of primary tumors, metastases and recurrences were assessed for fibroblast growth factor receptor 1 copy number status using fluorescence in situ hybridization. Human papilloma virus status was detected by p16 immunohistochemistry staining and PCR-ELISA. Molecular parameters were correlated with each other and with clinicopathological data. We found 15% of primary head and neck squamous cell carcinoma to display a fibroblast growth factor receptor 1 amplification. In nearly all cases, metastatic and recurrent tumor samples shared the same amplification status as the corresponding primary tumor. Fibroblast growth factor receptor 1 amplification was associated with nicotine and alcohol consumption, but was mutually exclusive with human papilloma virus infection. Amplification of the gene was associated with parameters of worse outcome. Our data identify fibroblast growth factor receptor 1 amplification as a frequent event in primary and metastatic head and neck squamous cell carcinoma and represents a potential biomarker for more aggressive disease. Fibroblast growth factor receptor 1-amplified tumors could potentially comprise a subset of head and neck squamous cell carcinoma against which targeted small-molecule inhibitors hold therapeutic efficacy.
AuthorsFriederike Göke, Maike Bode, Alina Franzen, Robert Kirsten, Diane Goltz, Antonia Göke, Rakesh Sharma, Diana Boehm, Wenzel Vogel, Patrick Wagner, Claudia Lengerke, Glen Kristiansen, Jutta Kirfel, Tobias Van Bremen, Friedrich Bootz, Lynn E Heasley, Andreas Schröck, Sven Perner
JournalModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Mod Pathol) Vol. 26 Issue 10 Pg. 1298-306 (Oct 2013) ISSN: 1530-0285 [Electronic] United States
PMID23619603 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1
Topics
  • Aged
  • Biomarkers, Tumor (genetics, metabolism)
  • Carcinoma, Squamous Cell (genetics, metabolism, pathology)
  • Female
  • Gene Amplification
  • Head and Neck Neoplasms (genetics, metabolism, pathology)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (genetics)
  • Receptor, Fibroblast Growth Factor, Type 1 (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: